

Hideyuki Takedani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1296400/publications.pdf>

Version: 2024-02-01

33
papers

284
citations

933447

10
h-index

940533

16
g-index

33
all docs

33
docs citations

33
times ranked

382
citing authors

#	ARTICLE	IF	CITATIONS
1	Extension contracture stiff knee in haemophilia: Surgical timing and procedure for total knee arthroplasty. <i>Modern Rheumatology</i> , 2023, 33, 851-855.	1.8	3
2	AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab " protocol for a multicentre, open-label, phase IV clinical study. <i>BMJ Open</i> , 2022, 12, e059667.	1.9	1
3	Surgical treatment of haemophilic pseudotumor with severe bone destruction: a case report. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 414-420.	0.7	0
4	Risk of deep venous thrombosis after total knee arthroplasty in patients with haemophilia A. <i>Haemophilia</i> , 2020, 26, 867-872.	2.1	10
5	Long-term impact of haemarthrosis on arthropathy and activities of daily living in Japanese persons with haemophilia. <i>Haemophilia</i> , 2020, 26, e124-e127.	2.1	1
6	Physical activity and its related factors in Japanese people with haemophilia. <i>Haemophilia</i> , 2019, 25, e267-e273.	2.1	8
7	Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 497-513.	1.8	14
8	Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: First multicentre study in Asia. <i>Haemophilia</i> , 2019, 25, e223-e230.	2.1	10
9	Perioperative safety and haemostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 385-392.	1.0	5
10	Orthotopic live transplantation for cirrhosis from hepatitis C virus leads to correction of factor IX deficiency allowing for ankle arthroplasty without factor replacement in a patient with moderate haemophilia B. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 131-134.	1.0	1
11	Perioperative safety and hemostatic efficacy of Advate® in patients with hemophilia A in a postmarketing surveillance in Japan. <i>International Journal of Hematology</i> , 2018, 108, 22-29.	1.6	3
12	A case report on a multicentre cooperative rehabilitation programme for inhibitor-positive patients with haemophilia A. <i>Haemophilia</i> , 2018, 24, e248-e252.	2.1	0
13	Risk factors for postoperative complications of orthopedic surgery in patients with hemophilia: Second report. <i>Journal of Orthopaedics</i> , 2018, 15, 558-562.	1.3	7
14	The Haemophilia Joint Visualizer: development of a personalized, interactive, web-based tool to help improve adherence to prophylaxis. <i>Haemophilia</i> , 2017, 23, e155-e158.	2.1	2
15	First report on the safety and efficacy of an extended half-life glyco-PEGylated recombinant FVIII for major surgery in severe haemophilia A. <i>Haemophilia</i> , 2017, 23, 689-696.	2.1	22
16	Usefulness of a simple self-administered joint condition assessment sheet to predict the need for orthopaedic intervention in the management of haemophilic arthropathy. <i>Haemophilia</i> , 2017, 23, e116-e123.	2.1	0
17	Arthroscopic debridement for advanced haemophilic ankle arthropathy. <i>Haemophilia</i> , 2017, 23, e479-e481.	2.1	3
18	A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2017, 23, 59-66.	2.1	19

#	ARTICLE	IF	CITATIONS
19	Strategies to encourage physical activity in patients with hemophilia to improve quality of life. <i>Journal of Blood Medicine</i> , 2016, 7, 85.	1.7	28
20	A successful physiotherapy management case of a patient with acquired haemophilia A prior to factor VIII inhibitor eradication. <i>Haemophilia</i> , 2016, 22, e228-31.	2.1	2
21	Major orthopaedic surgery for a haemophilia patient with inhibitors using a new bypassing agent. <i>Haemophilia</i> , 2016, 22, e459-61.	2.1	6
22	Total hip arthroplasty and total knee arthroplasty in a patient with congenital deficiency of plasminogen activator inhibitor-1. <i>Haemophilia</i> , 2016, 22, e237-9.	2.1	3
23	The features of clearance in recombinant factor IX (BeneFIX®). <i>Haemophilia</i> , 2015, 21, 702-707.	2.1	0
24	Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1767.	4.3	5
25	Joint Function and Arthropathy Severity in Patients with Hemophilia. <i>Journal of the Japanese Physical Therapy Association</i> , 2015, 18, 15-22.	0.1	14
26	Deep venous thrombosis was not detected after total knee arthroplasty in Japanese patients with haemophilia. <i>Haemophilia</i> , 2015, 21, 585-588.	2.1	15
27	First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol,) Tj ETQq1 1 0.784314 rgBT ₀ /Overlo 1.4		
28	Rehabilitation improved walking ability for three haemophilia patients with inhibitors. <i>Haemophilia</i> , 2014, 20, e222-4.	2.1	2
29	Self-monitoring has potential for home exercise programmes in patients with haemophilia. <i>Haemophilia</i> , 2014, 20, e121-7.	2.1	41
30	The risk of elective orthopaedic surgery for haemophilia patients: Japanese single-centre experience. <i>Haemophilia</i> , 2013, 19, 951-955.	2.1	14
31	Inter-observer reliability of three different radiographic scores for adult haemophilia. <i>Haemophilia</i> , 2011, 17, 134-138.	2.1	10
32	Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa. <i>Haemophilia</i> , 2010, 16, 290-295.	2.1	14
33	Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII. <i>Haemophilia</i> , 2010, 16, 740-746.	2.1	21